

Olle Ringden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5311376/publications.pdf>

Version: 2024-02-01

372
papers

37,250
citations

4388

86
h-index

3487

182
g-index

375
all docs

375
docs citations

375
times ranked

20620
citing authors

#	ARTICLE	IF	CITATIONS
1	Graft-versus-leukemia reactions after bone marrow transplantation. <i>Blood</i> , 1990, 75, 555-562.	1.4	2,566
2	Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. <i>Lancet, The</i> , 2004, 363, 1439-1441.	13.7	2,534
3	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. <i>Lancet, The</i> , 2008, 371, 1579-1586.	13.7	2,474
4	HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. <i>Experimental Hematology</i> , 2003, 31, 890-896.	0.4	1,510
5	Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex. <i>Scandinavian Journal of Immunology</i> , 2003, 57, 11-20.	2.7	1,274
6	Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease. <i>Transplantation</i> , 2006, 81, 1390-1397.	1.0	1,003
7	Graft-versus-leukemia reactions after bone marrow transplantation. <i>Blood</i> , 1990, 75, 555-62.	1.4	738
8	Immunomodulation by mesenchymal stem cells and clinical experience. <i>Journal of Internal Medicine</i> , 2007, 262, 509-525.	6.0	648
9	Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. <i>Transplantation</i> , 2003, 76, 1208-1213.	1.0	571
10	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. <i>Blood</i> , 2002, 100, 406-414.	1.4	503
11	Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation. <i>Stem Cells</i> , 2012, 30, 1575-1578.	3.2	456
12	Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. <i>Experimental Cell Research</i> , 2005, 305, 33-41.	2.6	448
13	Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 321-334.	2.0	429
14	Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. <i>Leukemia</i> , 2007, 21, 1733-1738.	7.2	406
15	Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta. <i>Transplantation</i> , 2005, 79, 1607-1614.	1.0	397
16	Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2000, 95, 3702-9.	1.4	378
17	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. <i>Blood</i> , 1994, 83, 2723-2730.	1.4	330
18	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. <i>Blood</i> , 1990, 75, 2459-2464.	1.4	326

#	ARTICLE	IF	CITATIONS
19	Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. <i>Blood</i> , 2000, 95, 807-814.	1.4	315
20	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. <i>Lancet Oncology</i> , The, 2012, 13, 366-374.	10.7	289
21	Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. <i>Trends in Molecular Medicine</i> , 2019, 25, 149-163.	6.7	288
22	Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 28, 73-82.	3.0	285
23	Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 557-564.	2.0	282
24	Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?. <i>Stem Cells</i> , 2012, 30, 1565-1574.	3.2	281
25	Mesenchymal Stem Cells Stimulate Antibody Secretion in Human B Cells. <i>Scandinavian Journal of Immunology</i> , 2007, 65, 336-343.	2.7	261
26	Allogeneic bone marrow transplantation for lysosomal storage diseases. <i>Lancet</i> , The, 1995, 345, 1398-1402.	13.7	254
27	Identical-Twin Bone Marrow Transplants for Leukemia. <i>Annals of Internal Medicine</i> , 1994, 120, 646.	3.9	252
28	Prophylaxis and treatment of GVHD: EBMTâ€™ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplantation</i> , 2014, 49, 168-173.	2.4	252
29	Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. <i>Journal of Clinical Oncology</i> , 2004, 22, 4872-4880.	1.6	246
30	Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. <i>Bone Marrow Transplantation</i> , 2012, 47, 203-211.	2.4	245
31	Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1998, 21, 995-1003.	2.4	240
32	Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4570-4577.	1.6	238
33	Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. <i>Blood</i> , 2002, 100, 1977-1983.	1.4	232
34	Graft failure in the modern era of allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 537-543.	2.4	223
35	Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. <i>Current Opinion in Immunology</i> , 2006, 18, 586-591.	5.5	202
36	KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 828-836.	2.0	201

#	ARTICLE	IF	CITATIONS
37	Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2004, 22, 2816-2825.	1.6	193
38	Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. <i>Leukemia</i> , 2007, 21, 2271-2276.	7.2	193
39	Busulfan bioavailability. <i>Blood</i> , 1994, 84, 2144-2150.	1.4	183
40	Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. <i>Blood</i> , 1992, 80, 1090-1093.	1.4	177
41	Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. <i>Bone Marrow Transplantation</i> , 1998, 22, 755-761.	2.4	176
42	Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2004, 22, 416-423.	1.6	173
43	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. <i>Blood</i> , 1993, 81, 1094-1101.	1.4	167
44	The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. <i>Blood</i> , 2007, 110, 4560-4566.	1.4	166
45	Graft Failure after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 165-170.	2.0	162
46	Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen-Identical Sibling Transplants for Adults With Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 5728-5734.	1.6	159
47	Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. <i>Lancet Haematology</i> , 2016, 3, e45-e52.	4.6	158
48	Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2011, 46, 200-207.	2.4	154
49	Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2004, 78, 122-127.	1.0	153
50	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 346-352.	3.5	153
51	Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. <i>Transfusion</i> , 1997, 37, 678-684.	1.6	151
52	RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1998, 66, 1330-1334.	1.0	150
53	Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. <i>Blood</i> , 2008, 112, 532-541.	1.4	149
54	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 113, 3110-3118.	1.4	147

#	ARTICLE	IF	CITATIONS
55	HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 3996-4003.	1.4	146
56	Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?. <i>Advances in Experimental Medicine and Biology</i> , 2016, 951, 77-98.	1.6	141
57	Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. <i>Blood</i> , 2002, 100, 4317-4324.	1.4	139
58	Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. <i>Haematologica</i> , 2010, 95, 2119-2125.	3.5	137
59	Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 4655-4664.	1.6	136
60	Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses. <i>PLoS ONE</i> , 2011, 6, e21703.	2.5	135
61	Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. <i>Bone Marrow Transplantation</i> , 2003, 31, 253-261.	2.4	134
62	A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. <i>British Journal of Haematology</i> , 1996, 93, 637-646.	2.5	133
63	The allogeneic graft-versus-cancer effect. <i>British Journal of Haematology</i> , 2009, 147, 614-633.	2.5	132
64	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1688-1697.	2.0	131
65	Outcome After Allogeneic Bone Marrow Transplant for Leukemia in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 1993, 270, 57.	7.4	127
66	Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. <i>Bone Marrow Transplantation</i> , 1995, 15, 619-25.	2.4	121
67	Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 823-830.	2.4	120
68	Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. <i>Leukemia</i> , 2001, 15, 1976-1985.	7.2	120
69	DEATH BY GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH HLA MISMATCH, HIGH RECIPIENT AGE, LOW MARROW CELL DOSE, AND SPLENECTOMY. <i>Transplantation</i> , 1985, 40, 39-44.	1.0	113
70	Outcome after allogeneic bone marrow transplant for leukemia in older adults. <i>JAMA - Journal of the American Medical Association</i> , 1993, 270, 57-60.	7.4	112
71	Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. <i>Blood</i> , 1992, 80, 1090-1093.	1.4	112
72	Intravenous Foscarnet for the Treatment of Severe Cytomegalovirus Infection in Allograft Recipients. <i>Scandinavian Journal of Infectious Diseases</i> , 1985, 17, 157-163.	1.5	111

#	ARTICLE	IF	CITATIONS
73	Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. <i>Transplantation</i> , 2004, 78, 122-7.	1.0	109
74	No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. <i>Blood</i> , 2001, 98, 1739-1745.	1.4	108
75	A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 553-561.	2.4	106
76	Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 889-893.	2.0	106
77	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010, 116, 4007-4015.	1.4	105
78	Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua. <i>Stem Cells and Development</i> , 2015, 24, 2269-2279.	2.1	104
79	Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1108-1115.	2.0	100
80	LONG-TERM FOLLOW-UP OF THE FIRST SUCCESSFUL BONE MARROW TRANSPLANTATION IN GAUCHER DISEASE. <i>Transplantation</i> , 1988, 46, 66-69.	1.0	96
81	A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10 ⁹ per L versus 30 x 10 ⁹ per L in allogeneic hematopoietic progenitor cell transplant recipients. <i>Transfusion</i> , 2005, 45, 1064-1072.	1.6	95
82	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. <i>Blood</i> , 1994, 83, 2723-30.	1.4	95
83	No Disadvantage in Outcome of Using Matched Unrelated Donors as Compared With Matched Sibling Donors for Bone Marrow Transplantation in Children With Acute Lymphoblastic Leukemia in Second Remission. <i>Journal of Clinical Oncology</i> , 2001, 19, 3406-3414.	1.6	92
84	Stromal cells from term fetal membrane are highly suppressive in allogeneic settings <i>in vitro</i> . <i>Clinical and Experimental Immunology</i> , 2012, 167, 543-555.	2.6	89
85	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
86	The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2006, 91, 1059-67.	3.5	89
87	Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. <i>Bone Marrow Transplantation</i> , 2006, 37, 1051-1059.	2.4	88
88	T CELL MIXED CHIMERISM IS SIGNIFICANTLY CORRELATED TO A DECREASED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION 1. <i>Transplantation</i> , 2001, 71, 433-439.	1.0	88
89	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. <i>Blood</i> , 1990, 75, 2459-64.	1.4	88
90	Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1996, 18, 921-9.	2.4	88

#	ARTICLE	IF	CITATIONS
91	The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. <i>Blood</i> , 2001, 98, 1982-1985.	1.4	87
92	The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. <i>Haematologica</i> , 2006, 91, 401-4.	3.5	87
93	The Highest Leukaemia-Free Survival After Allogeneic Bone Marrow Transplantation is Seen in Patients with Grade I Acute Graft-Versus-Host Disease. <i>Leukemia and Lymphoma</i> , 1996, 24, 71-79.	1.3	86
94	Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2006, 107, 1712-1716.	1.4	85
95	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. <i>Leukemia</i> , 2016, 30, 447-455.	7.2	85
96	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. <i>Annals of Oncology</i> , 2006, 17, 1134-1140.	1.2	84
97	Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Stem Cells</i> , 2013, 31, 592-601.	3.2	84
98	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	2.5	82
99	Increased Infection-Related Mortality in KIR-Ligand Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2004, 78, 1081-1085.	1.0	81
100	Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 65-72.	1.7	81
101	Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. <i>Bone Marrow Transplantation</i> , 1998, 22, 795-800.	2.4	80
102	Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. <i>British Journal of Haematology</i> , 1993, 83, 118-124.	2.5	79
103	Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. <i>Blood</i> , 1995, 86, 1614-1618.	1.4	79
104	BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. <i>Bone Marrow Transplantation</i> , 2008, 41, 737-742.	2.4	79
105	Graft-versus-myeloma effect. <i>Lancet</i> , The, 1996, 348, 346.	13.7	78
106	Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. <i>British Journal of Haematology</i> , 2003, 121, 874-885.	2.5	77
107	Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. <i>Stem Cells Translational Medicine</i> , 2018, 7, 325-331.	3.3	75
108	Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2002, 29, 391-397.	2.4	74

#	ARTICLE	IF	CITATIONS
109	Decidual Stromal Cells Promote Regulatory T Cells and Suppress Alloreactivity in a Cell Contact-Dependent Manner. <i>Stem Cells and Development</i> , 2013, 22, 2596-2605.	2.1	73
110	Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. <i>Tissue Antigens</i> , 2003, 62, 243-250.	1.0	72
111	Influenza B in Transplant Patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1989, 21, 349-350.	1.5	71
112	Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2000, 25, 843-851.	2.4	71
113	Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. <i>Clinical Transplantation</i> , 2001, 15, 147-153.	1.6	71
114	Variables predicting deep fungal infections in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1989, 4, 635-41.	2.4	71
115	N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2000, 25, 993-996.	2.4	70
116	Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. <i>Blood</i> , 2005, 105, 548-551.	1.4	70
117	Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. <i>Cytotherapy</i> , 2009, 11, 129-136.	0.7	69
118	Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2012, 89, 220-227.	2.2	69
119	Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. <i>Blood</i> , 2000, 95, 3323-7.	1.4	69
120	Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. <i>British Journal of Haematology</i> , 1986, 63, 671-679.	2.5	68
121	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). <i>Transplantation</i> , 2010, 90, 124-126.	1.0	66
122	Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. <i>Bone Marrow Transplantation</i> , 1991, 7, 221-6.	2.4	66
123	High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. <i>British Journal of Haematology</i> , 2000, 111, 774-781.	2.5	65
124	Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey. <i>Journal of Clinical Oncology</i> , 2002, 20, 4324-4330.	1.6	65
125	An analysis of factors predisposing to chronic graft-versus-host disease. <i>Experimental Hematology</i> , 1985, 13, 1062-7.	0.4	64
126	Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. <i>Leukemia</i> , 2000, 14, 247-254.	7.2	63

#	ARTICLE	IF	CITATIONS
127	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. <i>British Journal of Haematology</i> , 2000, 111, 1130-1137.	2.5	63
128	LOW INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE, USING UNRELATED HLA-A-, HLA-B-, AND HLA-DR-COMPATIBLE DONORS AND CONDITIONING, INCLUDING ANTI-T-CELL ANTIBODIES1. <i>Transplantation</i> , 1998, 66, 620-625.	1.0	63
129	A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. <i>Bone Marrow Transplantation</i> , 1986, 1, 41-51.	2.4	63
130	Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. <i>Nordic Bone Marrow Transplantation Group. Blood</i> , 1999, 93, 2196-201.	1.4	62
131	Alterations in taste acuity associated with allogeneic bone marrow transplantation. <i>Journal of Oral Pathology and Medicine</i> , 1992, 21, 33-37.	2.7	61
132	A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1417-1425.	3.5	61
133	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1975-1983.	2.0	61
134	B-Cell Mitogenic Effects on Human Lymphocytes of Rabbit Anti-Human beta2-Microglobulin. <i>Scandinavian Journal of Immunology</i> , 1975, 4, 171-179.	2.7	60
135	G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. <i>Bone Marrow Transplantation</i> , 2003, 32, 217-223.	2.4	60
136	Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. <i>Apmis</i> , 2005, 113, 813-830.	2.0	60
137	Lipid Formulations of Amphotericin B. <i>Drug Safety</i> , 1995, 13, 207-218.	3.2	59
138	A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2004, 78, 1014-1020.	1.0	59
139	Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Disorders: Experience in a Single Center. <i>Transplantation</i> , 2006, 81, 718-725.	1.0	59
140	Hemorrhagic cystitis: a retrospective single-center survey. <i>Clinical Transplantation</i> , 2007, 21, 659-667.	1.6	59
141	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-Up of a Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 135-138.	2.0	58
142	Generation of Immunosuppressive Mesenchymal Stem Cells in Allogeneic Human Serum. <i>Transplantation</i> , 2007, 84, 1055-1059.	1.0	57
143	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. <i>British Journal of Haematology</i> , 2015, 169, 711-718.	2.5	56
144	Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 574-585.	0.7	56

#	ARTICLE	IF	CITATIONS
145	Clinical and Biochemical Outcome of Marrow Transplantation for Gaucher Disease of the Norrbottnian Type. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1990, 79, 680-685.	1.5	55
146	One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood and Marrow Transplant Research Results in the Era of Molecular HLA Typing. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 640-648.	2.0	55
147	Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. <i>Blood</i> , 1983, 61, 1190-1195.	1.4	54
148	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 195-203.	2.0	53
149	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433.	3.5	53
150	HSCT Recipients Have Specific Tolerance to MSC but not to the MSC Donor. <i>Journal of Immunotherapy</i> , 2009, 32, 755-764.	2.4	51
151	FASTER IMMUNOLOGICAL RECOVERY AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITHOUT CYTOMEGALOVIRUS INFECTION. <i>Transplantation</i> , 1985, 39, 377-384.	1.0	50
152	Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. <i>Blood</i> , 1992, 79, 2771-2774.	1.4	50
153	Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. <i>Bone Marrow Transplantation</i> , 1999, 24, 629-635.	2.4	50
154	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning <scp>HSCT</scp> with unrelated donors. <i>Clinical Transplantation</i> , 2013, 27, E368-74.	1.6	50
155	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
156	Foscarnet for Treatment of Cytomegalovirus Infections in Bone Marrow Transplant Recipients. <i>Scandinavian Journal of Infectious Diseases</i> , 1992, 24, 143-150.	1.5	49
157	Infection of donor lymphocytes with human T lymphotropic virus type 1 (HTLV-1) following allogeneic bone marrow transplantation for HTLV-1 positive adult T-cell leukaemia. <i>British Journal of Haematology</i> , 1994, 88, 403-405.	2.5	49
158	Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. <i>Bone Marrow Transplantation</i> , 2003, 31, 23-29.	2.4	49
159	Hemorrhagic cystitis—a manifestation of graft versus host disease?. <i>Bone Marrow Transplantation</i> , 1987, 2, 19-25.	2.4	49
160	PRETRANSPLANT HERPESVIRUS SEROLOGY AND ACUTE GRAFT-VERSUS-HOST DISEASE. <i>Transplantation</i> , 1988, 46, 548-552.	1.0	48
161	Costs of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2006, 82, 147-153.	1.0	48
162	The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 31-38.	2.0	47

#	ARTICLE	IF	CITATIONS
163	Treatment of Severe Chronic Graft-Versus-Host Disease with Decidual Stromal Cells and Tracing with ¹¹¹ Indium Radiolabeling. <i>Stem Cells and Development</i> , 2015, 24, 253-263.	2.1	47
164	A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 831-836.	2.4	46
165	Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 128-134.	2.0	46
166	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.	4.1	46
167	Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. <i>Transplantation Proceedings</i> , 1989, 21, 2989-92.	0.6	46
168	Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. <i>Bone Marrow Transplantation</i> , 1997, 19, 963-968.	2.4	45
169	Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 706-715.	2.4	45
170	Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. <i>Bone Marrow Transplantation</i> , 2014, 49, 1046-1051.	2.4	44
171	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. <i>Blood</i> , 1993, 81, 1094-101.	1.4	44
172	Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 839844.	4.8	44
173	Graft-versus-leukemia reactions after bone marrow transplantation. <i>Blood</i> , 1990, 75, 555-562.	1.4	43
174	Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. <i>Blood</i> , 1992, 79, 2771-2774.	1.4	43
175	Allogeneic Bone Marrow Transplantation for Hematological Malignancies—Controversies and Recent Advances. <i>Acta Oncologica</i> , 1997, 36, 549-564.	1.8	42
176	Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 122, 788-794.	2.5	42
177	A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. <i>Journal of Internal Medicine</i> , 2013, 274, 153-162.	6.0	42
178	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. <i>Bone Marrow Transplantation</i> , 2017, 52, 400-408.	2.4	42
179	Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. <i>Bone Marrow Transplantation</i> , 1991, 7, 113-9.	2.4	42
180	Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. <i>Blood</i> , 1999, 94, 455-64.	1.4	42

#	ARTICLE	IF	CITATIONS
181	VARIABLES PREDICTING BACTERIAL AND FUNGAL INFECTIONS AFTER ALLOGENEIC MARROW ENGRAFTMENT. <i>Transplantation</i> , 1987, 43, 393-398.	1.0	41
182	Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 264-271.	2.0	41
183	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1418-1425.	2.0	40
184	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018, 96, 73-81.	2.8	40
185	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
186	Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. <i>Bone Marrow Transplantation</i> , 1999, 24, 389-396.	2.4	39
187	Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 511-516.	2.4	38
188	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1327-1334.	2.0	38
189	Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor. <i>Bone Marrow Transplantation</i> , 2008, 42, 643-648.	2.4	37
190	Case-Control Comparison of At-Home and Hospital Care for Allogeneic Hematopoietic Stem-Cell Transplantation: The Role of Oral Nutrition. <i>Transplantation</i> , 2008, 85, 1000-1007.	1.0	37
191	Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. <i>Clinical Transplantation</i> , 2011, 25, E68-E76.	1.6	37
192	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1589-1596.	2.0	37
193	Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis. <i>Frontiers in Immunology</i> , 2017, 8, 795.	4.8	37
194	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	5.2	37
195	Ten years' experience of bone marrow transplantation for Gaucher disease. <i>Transplantation</i> , 1995, 59, 864-70.	1.0	36
196	Establishment of a tissue bank for fetal stem cell transplantation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1994, 73, 385-388.	2.8	35
197	Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. <i>European Journal of Haematology</i> , 1997, 59, 254-262.	2.2	35
198	Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSCT treated patients. <i>International Journal of Hematology</i> , 2012, 96, 822-824.	1.6	35

#	ARTICLE	IF	CITATIONS
199	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
200	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
201	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
202	Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. <i>Bone Marrow Transplantation</i> , 1992, 9, 19-25.	2.4	35
203	Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. <i>Bone Marrow Transplantation</i> , 1987, 2, 299-305.	2.4	35
204	The Importance of Pre Bone Marrow Transplantation Serology in Determining Subsequent Cytomegalovirus Infection: An Analysis of Risk Factors. <i>Scandinavian Journal of Infectious Diseases</i> , 1986, 18, 199-209.	1.5	34
205	Hematopoietic stem cell transplantation in severe congenital neutropenia. <i>Pediatric Blood and Cancer</i> , 2011, 56, 444-451.	1.5	34
206	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
207	Increased serum concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1998, 77, 591-593.	2.8	33
208	Bone Marrow Transplantation in Three Patients with Multiple Myeloma. <i>Acta Medica Scandinavica</i> , 1986, 219, 523-527.	0.0	33
209	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
210	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
211	Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. <i>Journal of Internal Medicine</i> , 2012, 272, 472-483.	6.0	32
212	Stromal cells—are they really useful for GVHD?. <i>Bone Marrow Transplantation</i> , 2014, 49, 737-743.	2.4	32
213	Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. <i>Supportive Care in Cancer</i> , 2014, 22, 2133-2140.	2.2	32
214	Acyclovir prophylaxis in bone marrow transplant recipients. <i>Scandinavian Journal of Infectious Diseases, Supplement</i> , 1985, 47, 137-44.	0.3	32
215	The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. <i>Bone Marrow Transplantation</i> , 2000, 25, 1053-1058.	2.4	31
216	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. <i>Bone Marrow Transplantation</i> , 2012, 47, 831-837.	2.4	31

#	ARTICLE	IF	CITATIONS
217	A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplantation, 1990, 5, 321-6.	2.4	31
218	Cranio-mandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation. Acta Odontologica Scandinavica, 1994, 52, 99-105.	1.6	30
219	Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Human C1q Deficiency. Transplantation, 2016, 100, 1356-1362.	1.0	30
220	TRANSPLANTATION OF AUTOLOGOUS AND ALLOGENEIC BONE MARROW WITH LIVER FROM A CADAVERIC DONOR FOR PRIMARY LIVER CANCER1. Transplantation, 2000, 69, 2043-2048.	1.0	30
221	European experience of bone marrow transplantation for leukemia. Transplantation Proceedings, 1987, 19, 2600-4.	0.6	30
222	Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors—a single centre study. Bone Marrow Transplantation, 2008, 41, 399-405.	2.4	29
223	Granulocyte Colony-Stimulating Factor Induced Acute and Chronic Graft-Versus-Host Disease. Transplantation, 2010, 90, 1022-1029.	1.0	29
224	Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplantation, 2000, 26, 1057-1060.	2.4	28
225	A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 1161-1166.	2.4	28
226	Immunotherapy by Allogeneic Stem Cell Transplantation. Advances in Cancer Research, 2007, 97, 25-60.	5.0	28
227	Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation. Acta Haematologica, 2018, 139, 106-114.	1.4	28
228	LONG-TERM FOLLOW-UP OF A RANDOMIZED TRIAL COMPARING T CELL DEPLETION WITH A COMBINATION OF METHOTREXATE AND CYCLOSPORINE IN ADULT LEUKEMIC MARROW TRANSPLANT RECIPIENTS. Transplantation, 1994, 58, 887-891.	1.0	27
229	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 326-335.	2.0	27
230	Are Increased IgE-Levels a Signal of an Acute Graft-Versus-Host Reaction?. Immunological Reviews, 1983, 71, 57-76.	6.0	26
231	Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplantation, 1998, 21, 43-49.	2.4	26
232	Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation. Orthodontics and Craniofacial Research, 2012, 15, 21-29.	2.8	26
233	Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation — A comparison of the last two decades. Pediatric Transplantation, 2016, 20, 667-674.	1.0	26
234	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2017, 176, 431-439.	2.5	26

#	ARTICLE	IF	CITATIONS
235	Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. <i>Transplantation Proceedings</i> , 1997, 29, 733-734.	0.6	25
236	Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000, 25, S6-S8.	2.4	25
237	Management of graft-versus-host disease. <i>European Journal of Haematology</i> , 1993, 51, 1-12.	2.2	25
238	Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1728-1737.	2.0	25
239	Mesenchymal stromal cells as treatment for chronic GVHD. <i>Bone Marrow Transplantation</i> , 2011, 46, 163-164.	2.4	24
240	Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. <i>European Journal of Haematology</i> , 2011, 87, 503-509.	2.2	24
241	Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study. <i>Blood</i> , 2009, 114, 663-663.	1.4	24
242	The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. <i>Bone Marrow Transplantation</i> , 2002, 30, 761-768.	2.4	23
243	Liposomal amphotericin B (AmBisome®) treatment of invasive fungal infections in immunocompromised children. <i>Mycoses</i> , 1993, 36, 187-192.	4.0	23
244	Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. <i>European Journal of Haematology</i> , 1993, 50, 269-274.	2.2	23
245	Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation. <i>Transfusion</i> , 2015, 55, 2339-2350.	1.6	23
246	Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. <i>Bone Marrow Transplantation</i> , 1988, 3, 281-90.	2.4	23
247	Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 314-320.	2.0	22
248	Bone marrow aspiration technique has deteriorated in recent years. <i>Bone Marrow Transplantation</i> , 2015, 50, 1007-1009.	2.4	22
249	INCREASED LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR IN VENO-OCCLUSIVE DISEASE OF THE LIVER AFTER ALLOGENIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1995, 60, 1293-1298.	1.0	22
250	Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. <i>Pediatric Transplantation</i> , 1997, 1, 124-9.	1.0	22
251	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
252	Variables predicting oral mucosal lesions in allogeneic bone marrow recipients. <i>Head and Neck</i> , 1991, 13, 224-229.	2.0	20

#	ARTICLE	IF	CITATIONS
253	Factors With an Impact on Chimerism Development and Long-Term Survival After Umbilical Cord Blood Transplantation. <i>Transplantation</i> , 2012, 94, 1066-1074.	1.0	20
254	Immunogenicity of Decidual Stromal Cells in an Epidermolysis Bullosa Patient and in Allogeneic Hematopoietic Stem Cell Transplantation Patients. <i>Stem Cells and Development</i> , 2015, 24, 1471-1482.	2.1	20
255	Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2685.	4.8	20
256	Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10554-10564.	3.6	20
257	Bone marrow transplantation using unrelated donors for haematological malignancies. <i>Medical Oncology</i> , 1997, 14, 11-22.	2.5	19
258	Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. <i>Bone Marrow Transplantation</i> , 2007, 39, 383-388.	2.4	19
259	Pooled MSCs for treatment of severe hemorrhage. <i>Bone Marrow Transplantation</i> , 2011, 46, 1158-1160.	2.4	19
260	Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4941-4943.	3.2	19
261	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	1.6	19
262	Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans ¹ . <i>Transplantation</i> , 2003, 75, 1061-1066.	1.0	18
263	Treatment Costs and Survival in Patients with Grades III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation During Three Decades. <i>Transplantation</i> , 2006, 81, 1600-1603.	1.0	18
264	Similar Outcome After Unrelated Allogeneic Peripheral Blood Stem Cell Transplantation Compared With Bone Marrow in Children and Adolescents. <i>Transplantation</i> , 2007, 84, 551-554.	1.0	17
265	Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study. <i>Tissue Antigens</i> , 2008, 72, 549-558.	1.0	17
266	Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo. <i>Cytotherapy</i> , 2015, 17, 1732-1745.	0.7	17
267	Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. <i>European Journal of Haematology</i> , 2008, 80, 419-428.	2.2	16
268	Bone marrow transplantation for metabolic disorders at Huddinge Hospital. <i>Transplantation Proceedings</i> , 1990, 22, 198-202.	0.6	16
269	Pretransplant herpes virus serology and chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1989, 4, 547-52.	2.4	16
270	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. <i>Medical Oncology</i> , 2018, 35, 79.	2.5	15

#	ARTICLE	IF	CITATIONS
271	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
272	Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF- α and AP-1 Signaling. <i>Frontiers in Immunology</i> , 2021, 12, 774052.	4.8	15
273	Use of Mitogens for the Functional Characterization of Human Lymphocyte Subpopulations. <i>Scandinavian Journal of Immunology</i> , 1976, 5, 125-134.	2.7	14
274	Mesenchymal Stem Cells Combined with Cyclosporine Inhibits Cytotoxic T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 693-694.	2.0	14
275	Mesenchymal Stromal Cells as First-Line Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation. <i>Stem Cells and Development</i> , 2009, 18, 1243-1246.	2.1	14
276	GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. <i>European Journal of Haematology</i> , 2010, 84, 323-331.	2.2	14
277	Increased risk of gastrointestinal acute <scp>GVHD</scp> following the addition of melphalan to busulfan/cyclophosphamide conditioning. <i>Pediatric Transplantation</i> , 2013, 17, 285-293.	1.0	14
278	Frontline Science: Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells. <i>Journal of Leukocyte Biology</i> , 2017, 101, 623-632.	3.3	14
279	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1965-1969.	2.0	14
280	Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan. <i>Oral Oncology</i> , 2011, 47, 915-919.	1.5	13
281	Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. <i>BMC Immunology</i> , 2014, 15, 25.	2.2	13
282	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	5.2	13
283	Can we prevent or treat graft-versus-host disease with cellular-therapy?. <i>Blood Reviews</i> , 2020, 43, 100669.	5.7	13
284	Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning. <i>Oncotarget</i> , 2016, 7, 30230-30240.	1.8	13
285	Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. <i>Bone Marrow Transplantation</i> , 1994, 14 Suppl 5, S10-4.	2.4	13
286	GRAFT-VERSUS-LEUKAEMIA ACTIVITY ASSOCIATED WITH CYTOMEGALOVIRUS ANTIBODY POSITIVE BONE MARROW DONORS IN ACUTE MYELOID LEUKAEMIA. <i>Lancet, The</i> , 1987, 329, 456-457.	13.7	12
287	Engraftment and tumor formation after allogeneic in utero transplantation of primate embryonic stem cells.. <i>Transplantation</i> , 2003, 76, 1011-1012.	1.0	12
288	Indium- 111 -Labelled Donor-Lymphocyte Infusion by way of Hepatic Artery and Radio-Frequency Ablation against Liver Metastases of Renal and Colon Carcinoma after Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2004, 78, 697-703.	1.0	12

#	ARTICLE	IF	CITATIONS
289	A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation. <i>Archives of Drug Information</i> , 2008, 1, 89-96.	1.6	12
290	Intra-arterial Administration of Placenta-Derived Decidual Stromal Cells to the Superior Mesenteric Artery in the Rabbit: Distribution of Cells, Feasibility, and Safety. <i>Cell Transplantation</i> , 2016, 25, 401-410.	2.5	12
291	Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 760.	4.8	12
292	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
293	Successful Treatment with Prednisone of Graft-versus-Host Disease in an Allogeneic Bone-marrow Transplant Recipient. <i>Scandinavian Journal of Haematology</i> , 1979, 22, 333-338.	0.0	11
294	Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia?. <i>Transplantation</i> , 2014, 98, 569-577.	1.0	11
295	The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients. <i>Supportive Care in Cancer</i> , 2015, 23, 1749-1757.	2.2	11
296	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2018, 107, 478-485.	1.6	11
297	Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 567210.	4.8	11
298	Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI. <i>Oral Diseases</i> , 2011, 17, 670-676.	3.0	10
299	What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?. <i>Journal of Internal Medicine</i> , 2018, 283, 166-177.	6.0	10
300	Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical and Translational Science</i> , 2020, 13, 293-300.	3.1	10
301	High cure rate of invasive fungal infections in immunocompromised children using ambisome. <i>Transplantation Proceedings</i> , 1994, 26, 175-7.	0.6	10
302	Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. <i>Pediatric Transplantation</i> , 2014, 18, 398-404.	1.0	9
303	Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome. <i>Lancet Respiratory Medicine</i> , 2015, 3, e12.	10.7	9
304	Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 676-681.	2.0	9
305	Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research. <i>Blood</i> , 2008, 112, 348-348.	1.4	9
306	Allogeneic Bone Marrow Transplantation Versus Chemotherapy in Children with Acute Leukemia in Sweden. <i>Pediatric Hematology and Oncology</i> , 1989, 6, 137-144.	0.8	8

#	ARTICLE	IF	CITATIONS
307	Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 51-55.	3.0	8
308	Introduction to graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 17-20.	2.0	8
309	Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 213-218.	2.4	8
310	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2006, 108, 5304-5304.	1.4	8
311	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 679-679.	1.4	8
312	A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. <i>Transplantation Proceedings</i> , 1994, 26, 1831-2.	0.6	8
313	Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1995, 16, 856-7.	2.4	8
314	Oral mucous membrane lesions in children treated with bone marrow transplantation. <i>European Journal of Oral Sciences</i> , 1989, 97, 268-277.	1.5	7
315	No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells. <i>Cytotherapy</i> , 2008, 10, 238-242.	0.7	7
316	Simultaneously presenting aplastic anaemia and Hodgkin's disease successfully treated with allogeneic bone marrow transplantation. <i>European Journal of Haematology</i> , 1991, 46, 314-316.	2.2	7
317	TCR+CD4 ⁺ CD8 ⁺ T cells in Antigen-specific MHC Class II-restricted T-cell Responses After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Immunotherapy</i> , 2014, 37, 416-425.	2.4	7
318	Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. <i>Blood</i> , 1983, 61, 1190-5.	1.4	7
319	Activation of Human T and B Cells by Rabbit Anti-Human beta2-Microglobulin. <i>Scandinavian Journal of Immunology</i> , 1980, 11, 121-130.	2.7	6
320	Serum levels of alpha-1 microglobulin and beta-2 microglobulin in bone marrow transplant recipients treated with cyclosporin A. <i>Transplant International</i> , 1991, 4, 146-150.	1.6	6
321	<i>Pediatric Transplantation</i>: Ten years on. <i>Pediatric Transplantation</i> , 2009, 13, 272-277.	1.0	6
322	Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 1541-1542.	2.4	6
323	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
324	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2014, 124, 422-422.	1.4	6

#	ARTICLE	IF	CITATIONS
325	THE FIRST INFANT TO SURVIVE A GENERALIZED BCG INFECTION. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 161-165.	1.5	5
326	Serum levels of alpha-1 microglobulin in recipients of renal allografts. Transplant International, 1989, 2, 23-26.	1.6	5
327	Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease. Implications for its use?. Medical Oncology, 2007, 24, 354-356.	2.5	5
328	Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. British Journal of Haematology, 2012, 157, 220-229.	2.5	5
329	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. Journal of Immunotherapy, 2017, 40, 132-139.	2.4	5
330	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood, 1990, 75, 2459-2464.	1.4	5
331	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood, 1994, 83, 2723-2730.	1.4	5
332	Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation. Transplantation Proceedings, 1995, 27, 3530.	0.6	5
333	Isoamylase levels in bone marrow transplant patients are affected by total body irradiation and not by graft-versus-host disease. Transplant International, 1991, 4, 96-98.	1.6	4
334	Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease and Graft Failure After Hematopoietic Stem Cell Transplantation and Future Challenges. , 2013, , 173-205.		4
335	Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease. Pediatric Transplantation, 2017, 21, e12990.	1.0	4
336	Treatment of radiculomyelopathy in two patients with placenta-derived decidual stromal cells. International Journal of Hematology, 2020, 111, 591-594.	1.6	4
337	Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis. Oral Diseases, 2021, 27, 1217-1225.	3.0	4
338	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	1.2	4
339	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 2918-2918.	1.4	4
340	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood, 1993, 81, 1094-1101.	1.4	4
341	Polyclonal Antibody Secretion during Acute Graft-versus-Host Disease. Scandinavian Journal of Immunology, 1987, 26, 469-476.	2.7	3
342	Craniofacial growth in bone marrow transplant recipients treated with growth hormone after total body irradiation. European Journal of Oral Sciences, 1991, 99, 44-47.	1.5	3

#	ARTICLE	IF	CITATIONS
343	Response to Dr Furebring. Bone Marrow Transplantation, 2000, 25, 342-343.	2.4	3
344	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. Medical Oncology, 2012, 29, 2348-2358.	2.5	3
345	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. Transplantation, 2019, 103, 1247-1252.	1.0	3
346	Busulfan bioavailability. Blood, 1994, 84, 2144-2150.	1.4	3
347	DNA synthesis in human blood mononuclear cells correlates with severity of acute graft-versus-host disease. Bone Marrow Transplantation, 1987, 2, 259-69.	2.4	3
348	Decreased transplant-related complications and improved leukemia-free survival in adults receiving methotrexate combined with cyclosporin compared with either agent alone for prevention of graft-versus-host disease. Advisory Committee of the International Bone Marrow Transplant Registry. Transplantation Proceedings, 1993, 25, 1241-2.	0.6	3
349	Correlation of pretransplant viral serology and complications of bone marrow transplantation. Annals of Hematology, 1992, 64, A143-A147.	1.8	2
350	Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases. Bone Marrow Transplantation, 2006, 38, 321-322.	2.4	2
351	Increased Frequency and Responsiveness of PSA-Specific T Cells After Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2009, 87, 467-472.	1.0	2
352	Is Graft-versus-Leukemia More Effective Using Reduced-Intensity Conditioning Compared with Myeloablative Conditioning?. Biology of Blood and Marrow Transplantation, 2012, 18, 1615-1617.	2.0	2
353	Superselective intra-arterial umbilical cord blood administration to BM in experimental animals. Bone Marrow Transplantation, 2014, 49, 1486-1491.	2.4	2
354	Photochemotherapy of Cutaneous Graft-versus-Host Disease May Reduce Concomitant Visceral Disease. Dermatology, 2016, 232, 453-463.	2.1	2
355	Serum levels of alpha-1 microglobulin in recipients of renal allografts. Transplant International, 1989, 2, 23-26.	1.6	2
356	Immunodeficiency associated with bone marrow transplantation. Current Opinion in Immunology, 1989, 1, 497-501.	5.5	1
357	Transplantation with unrelated bone marrow in leukemic patients above 40 years of age. Transplantation Proceedings, 1997, 29, 3145-3146.	0.6	1
358	Photochemotherapy and Graft-versus-Leukemia Reaction in Acute Leukemia: Tumor Immunity and Survival Are Dependent on Timing of Photochemotherapy of the Skin. Dermatology, 2017, 233, 303-313.	2.1	1
359	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. International Journal of Hematology, 2021, 113, 712-722.	1.6	1
360	Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.. Blood, 2009, 114, 53-53.	1.4	1

#	ARTICLE	IF	CITATIONS
361	Allogeneic bone marrow transplantation: the Huddinge experience. Transplantation Proceedings, 1992, 24, 371-3.	0.6	1
362	Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survival. Clinical Transplants, 1990, , 175-87.	0.2	1
363	Transplantation of peripheral blood progenitor cells from unrelated donors. Bone Marrow Transplantation, 1996, 17 Suppl 2, S62-4.	2.4	1
364	Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Bone Marrow Transplantation, 1998, 21 Suppl 3, S81-4.	2.4	1
365	Fatal Infectious Complications Developing Late after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 3239-3239.	1.4	0
366	Recent Decrease in Acute GVHD and Increased Relapse in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants.. Blood, 2007, 110, 1081-1081.	1.4	0
367	Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT. Blood, 2009, 114, 3364-3364.	1.4	0
368	Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.. Blood, 2009, 114, 3320-3320.	1.4	0
369	Graft Failure In Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4559-4559.	1.4	0
370	Human C1q Deficiency and Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 5922-5922.	1.4	0
371	Spontaneous antibody secretion and DNA synthesis in blood lymphocytes increase during acute graft-versus-host disease. Transplantation Proceedings, 1988, 20, 503-5.	0.6	0
372	Allogeneic bone marrow transplantation in children at Huddinge Hospital. Transplantation Proceedings, 1988, 20, 487-90.	0.6	0